Novocure Ltd
NASDAQ:NVCR
Operating Margin
Novocure Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| JE |
|
Novocure Ltd
NASDAQ:NVCR
|
2B USD |
-27%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.7B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
193.3B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
154.6B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.5B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.8B USD |
19%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
53.2B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.4B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.8B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.5B CNY |
34%
|
Novocure Ltd
Glance View
Novocure Ltd. operates in the intriguing intersection of medical innovation and patient-centric care, focusing on harnessing electric fields to treat cancerous tumors, a modality known as Tumor Treating Fields (TTFields). Founded in 2000 and based in the Isle of Jersey, the company has pioneered an unconventional approach that challenges traditional cancer treatments like chemotherapy and radiation. By deploying low-intensity, alternating electric fields through adhesive patches on the patient's body, TTFields interfere with the division of cancer cells, inhibiting tumor growth without the typical debilitating side effects. Novocure’s proprietary technology offers a unique, non-invasive treatment option primarily targeting aggressive cancers, such as glioblastoma and non-small cell lung cancer, positioning it as a notable innovator in the oncology space. The company's business model thrives on a blend of therapy innovation and strategic partnerships. Novocure generates revenue through sales of its wearable medical device, which continually delivers TTFields therapy. These sales are supplemented by the securing of insurance reimbursements, which is crucial for patient access and company profitability. By conducting numerous clinical trials, Novocure not only aims to expand the applicability of TTFields to other forms of cancer but also reinforces its value proposition to the healthcare community. Strategic collaborations with researchers and leading cancer centers further enhance its market penetration. As the company continues to invest in research and expand its treatment portfolio, its commitment to transforming cancer therapy by offering a new dimension of hope remains at the forefront of its mission.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Novocure Ltd's most recent financial statements, the company has Operating Margin of -26.8%.
You don't have any saved screeners yet